Therapeutic Area: Cancer

Phase 2 Combination Study in Glioblastoma Multiforme

Status: Ongoing, Recruiting Patients

This is an open-label, dose finding, multiple-dose study in subjects with recurring/relapsing glioblastoma multiforme. Three dose levels of MPC-6827 will be administered with carboplatin to three separate cohorts. Study endpoints will include determination of the maximum tolerated dose, dose limiting toxicities, and evaluation of evidence of anti-tumor activity of MPC-6827 when given with carboplatin.

Visit clinicaltrials.gov for more information:
http://clinicaltrials.gov/ct2/show/NCT00635557

Phase 2 Combination Study in Metastatic Melanoma

Status: Ongoing, Enrollment Complete

This is an open-label, dose finding, multiple-dose study in subjects with metastatic melanoma. Three dose levels of MPC-6827 will be administered with temozolomide to three separate cohorts. Study endpoints will include determination of the maximum tolerated dose, determination of dose limiting toxicities, and evaluation of evidence of anti-tumor activity of MPC-6827 when given with temozolomide.

Visit clinicaltrials.gov for more information:
http://clinicaltrials.gov/ct2/show/NCT00609011

Phase 2 Monotherapy Study in Glioblastoma Multiforme

Status: Ongoing, Recruiting Patients

This is an open-label, multiple-dose study in subjects with glioblastoma multiforme. The primary endpoint for this study is 6-month Progression Free Survival (PFS) compared against historical control. The secondary endpoints include overall response observed over a maximum of 18 months of follow-up and overall survival. This study is being conducted at 10 sites in the US.

Visit clinicaltrials.gov for more information:
http://www.clinicaltrials.gov/ct2/show/NCT00892931

Phase 1 Clinical Trial (Metastatic Solid Tumors, with or without brain metastases)

Status: Completed

Myriad has completed a Phase 1 clinical trial for Azixa™ (MPC-6827) at the M.D. Anderson Cancer Center in Houston and the Huntsman Cancer Center in Salt Lake City. The study was designed to evaluate the safety and pharmacokinetic profile of MPC-6827 in patients with advanced solid tumors, in an escalating dose regimen.

Visit clinicaltrials.gov for more information:
http://www.clinicaltrials.gov/ct/show/NCT00394446

Phase 1 Clinical Trial (Metastatic Brain Cancer)

Status: Completed

Myriad has completed an open label, dose escalating, multiple dose study to determine the safety, tolerability, maximum tolerated dose, and pharmacokinetics of MPC-6827 in subjects with refractory brain metastases. This study was performed at the M.D. Anderson Cancer Center in Houston.

Visit clinicaltrials.gov for more information:
http://www.clinicaltrials.gov/ct/show/NCT00393965

Contact Us: This e-mail address is being protected from spambots. You need JavaScript enabled to view it